Longboard Pharmaceuticals price target raised to $34 from $32 at Wedbush

Wedbush raised the firm’s price target on Longboard Pharmaceuticals to $34 from $32 and keeps an Outperform rating on the shares. The Q1 update from Longboard was overall as anticipated, following the recent presentation of detailed bexicaserin PACIFIC data at the AAN conference, the analyst tells investors in a research note. Looking ahead, Wedbush is focused on learning more about the regulatory and development strategy as Longboard prepares to initiate registrational studies by the end of the year.